Export 7 results:
[ Author(Desc)] Title Type Year
Filters: Author is Cruz, F.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Cruz, F., Herschorn, S., Aliotta, P., Brin, M., et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. European Urology, 60(4), 742 - 750.
Cruz, F., & Desgrandchamps, F. (2010). New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men. European Urology, Supplements, 9(4), 472 - 476.
Cruz, F., Silva, J., Pinto, R., Carvallho, T., et al. (2009). Reply to Tomasz Drewa, Zbigniew Wolski and Janusz Tyloch's Letter to the Editor re: João Silva, Rui Pinto, Tiago Carvallho, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur. European Urology, 56(5), e28 - e29.
Cruz, F., & Dinis, P. (2007). Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourology and Urodynamics, 26(6 SUPPL.), 920 - 927.
Cruz, F., & Silva, C. (2004). Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Current Opinion in Urology, 14(6), 329 - 334.
Cruz, F. (2004). Mechanisms involved in new therapies for overactive bladder. Urology, 63(3 SUPPL. 1), 65 - 73.
Cruz, F. (2016). Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European Urology, 70(5), 892.

Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@ibmc.up.pt | © copyright 2010 ibmc